NCT04657822Active, not recruitingPhase 4
Rollover Study for Patients with Sickle Cell Disease who have Completed a prior Novartis-Sponsored Crizanlizumab Study
An Open-label, Multi-center, Phase IV, Rollover Study for Patients with Sickle Cell Disease who have Completed a Prior Novartis-Sponsored Crizanlizumab Study
Source: EU CTIS (euclinicaltrials.eu) · Last updated 30 Oct 2026
Brief summary (registry, in English)
To allow access of crizanlizumab to patients with SCD who are on crizanlizumab treatment in a Novartis-sponsored study
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 22 (estimated)
- First submitted
- 29 Feb 2024
- Start date
- 10 Jun 2021
- Lead sponsor
- Novartis Pharma AG
- Diseases
- Sickle cell disease
- NCT number
- NCT04657822
- EU CT number
- 2024-510734-41-00
- EudraCT number
- 2020-004225-22
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 22
- 7 sites in 5 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Concurrent participation in any other investigational clinical trial other than the parent study or plan to participate in any other investigational clinical trial
- Women of childbearing potential who are unwilling to be on highly effective contraceptives during dosing and until 15 weeks after stopping treatment with crizanlizumab
Other
- Patient had permanently discontinued from crizanlizumab study treatment in the parent study before the parent study completion
- Ongoing/unresolved treatment-related Grade 3 or higher AEs, and/or any ongoing AE requiring dose interruption
- Pregnant or nursing women
Who the study is looking for
- Written informed consent/assent, according to local guidelines, signed by the adult patients.
- SCD patient currently enrolled and benefitting from a Novartis-sponsored study receiving crizanlizumab and has fulfilled all the requirements
- Patient has demonstrated compliance to the planned visit schedule in the parent study, and in the opinion of the investigator has shown willingness and ability to comply with future visit schedules
Sex: All · Does not accept healthy volunteers
Sites (7)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Association Hospitaliere De Bruxelles Hopital Universitaire Des Enfants Reine Fabiola Coordinator of this site? Confirm its status | Brussels | Belgium | Active, not recruiting |
| Centre Hospitalier Regional de la Citadelle Coordinator of this site? Confirm its status | Liège | Belgium | Active, not recruiting |
| Universitaetsklinikum Heidelberg AöR Coordinator of this site? Confirm its status | Heidelberg | Germany | Active, not recruiting |
| Vall d'Hebron Institute of Oncology Coordinator of this site? Confirm its status | Barcelona | Spain | Active, not recruiting |
| Hospital General Universitario Gregorio Marañón Coordinator of this site? Confirm its status | Madrid | Spain | Active, not recruiting |
| Hopital Necker Enfants Malades Coordinator of this site? Confirm its status | Paris | France | Active, not recruiting |
| Azienda Ospedale Universita Padova Coordinator of this site? Confirm its status | Padova | Italy | Active, not recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.